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Abstract 
 
5-Lipoxygenase metabolizes arachidonic acid (AA) to generate leukotrienes 
(LTs). Leukotrienes are very potent inflammatory mediators that can have negative 
effects on bone healing and cartilage tissue generation. Recent studies have shown that 
decreasing 5-lipoxygenase (5-LO) activity during fracture healing accelerates 
endochondral ossification and decreases healing time in animal fracture models, however, 
the roles of 5-LO in chondrogenesis is not fully investigated. In this study, we tested the 
hypothesis that 5-LO inhibition will increase the process of chondrogenesis. The ABT- 
761 is an N-hydroxyurea analog structurally similar to zileuton, which is a 5-LO enzyme 
inhibitor. The ATDC5 cell line which is derived from teratocarcinoma cells of mice is a 
chondrogenic cell line. The ATDC5 cells were treated with ABT-761 and Insulin. Then, 
they were evaluated for cellular proliferation via colorimetric assay, 5-LO gene 
expression via Immunocytochemistry (ICC) and Immunoblotting (Western Blot), and 
chondrogenesis by measuring calcium deposition, proteoglycan synthesis via Alizarin 
Red stain and Alcian Blue stain respectively at specific time points 7 days, 14 days, 21 
days and 28 days. Our data demonstrated that ATDC5 cells express a 5-LO protein which 
can be directly inhibited by ABT-761 treatment. At a concentration of 10 µM, ABT-761 
treatment does not affect ATDC5 cellular proliferation, however, higher doses inhibit 
significantly. In term of chondrogenesis, in this study, we demonstrated that 1µM ABT- 
761 has no effect on chondrogenesis, neither increase nor decrease, in ATDC5 
chondrogenic cell line. In contrast, concentrations of 10 µM and 100µM ABT-761 have 
negative effects on chondrogenesis through which ABT-761 promotes chondrocyte 
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apoptosis that may potentially lead to accelerating endochondral ossification or long bone 
formation in patients with a long bone fracture. However, ABT-761 may not be a clinical 
value to regenerate or promote chondrogenesis in patients suffering from osteoarthritis. 
 
 
 
Key words: osteoarthritis, chondrocyte, chondrogenesis, ossification, ABT-761, 
 
ATDC5 cell.
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Introduction 
 
Cartilage biology 
 
Cartilage is a strong, flexible and semi-rigid supporting connective tissue. Like all 
connective tissue, cartilage consists of cells called chondrocytes and extracellular matrix 
(ECM). Chondrocytes are highly specialized cells which are derived from mesenchymal 
stem cells and occupy from 1% to 5% of total cartilage tissue (Bhosale and Richardson 
2008). They are metabolically active cells that proliferate and secrete ECM to maintain, 
sustain, and repair the cartilage (Akkiraju and Nohe 2015). Cartilaginous extracellular 
matrix is composed of 70-80% water, 10-25% collagen fibers which have high amounts 
of type II collagen, and 5-15% proteoglycans (PGs) which have a large composition of 
aggrecans (Horkay 2012) that contain non-collagenous protein and glycoproteins 
including glycosaminoglycan (GAG) and hyaluronic acid (HA) (Gao, Liu et al. 2014). 
Water and proteoglycans provide cartilage tissues compressive strength while the 
collagenous network is responsible for the tensile strength (Bautista, Park et al. 2016). 
The three-dimensional network of ECM is formed by the triple-helical collagen fibrils. 
The major cartilage PG is the bottle brush aggrecan molecule, which interacts with 
hyaluronic acid (HA) to form large proteoglycan aggregates (size 1-4 micrometers) or 
aggrecan-HA complexes. These complexes are embedded in the fibrous collagenous 
network (Horkay 2012) (Figure 1). 
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There are three types of cartilages, including hyaline cartilage, elastic cartilage, 
and fibrous cartilage. Elastic cartilage is found at the external ear, ear canal, epiglottis of 
the larynx. Fibrous cartilage is found in intervertebral disks of the vertebral column and 
menisci of the knee, forms the attachment of ligaments and tendons to bone. Hyaline 
cartilage comprises cartilage at synovial joint including shoulders, elbow, hips, sternum, 
and cartilage of nasal septum, larynx, trachea, and bronchi. Hyaline cartilage is also 
called articular cartilage and is 2-4 mm thick (Sophia Fox, Bedi et al. 2009). There are 
two important functions that articular cartilage performs. First, along with synovial fluid, 
articular cartilage provides virtually friction-free movement within the joint. Second, 
cartilage spreads the load in weight-bearing joints across the joint surface, which allows 
the underlying bones to absorb the shock and weight. Hence, articular cartilage functions 
require it to be elastic and to have high tensile strength. These characteristics are 
provided by ECM components, proteoglycans and Type II collagen, which are both 
produced by chondrocytes (Bautista, Park et al. 2016). Similar to bone tissue, cartilage 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 shows the hierarchy of cartilage extracellular matrix 
organization. (A) Aggrecan bottlebrush. (B) Aggrecan-HA complex. 
(C) Aggrecan-HA complexes aggregates in the collagenous network 
(Horkay 2012) 
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degrades and replaces its matrix constantly. Unlike bone tissue, however, cartilage is 
devoid of blood vessels, lymphatics and nerves, therefore, cartilage has very limited 
capability to heal and repair in a harsh biochemical condition (Sophia Fox, Bedi et al. 
2009). Nutrition is supplied through simple diffusion of synovial fluid. Thus, the 
regeneration capacity of articular cartilage is very limited. As a result, injuries that do not 
penetrate the subchondral bone cannot self-repair in adults (Dehne, Karlsson et al. 2009). 
 
 
 
Chondrogenesis and chondrocyte differentiation during development 
 
Cartilage has an important function by serving as a template for long bone 
formation through endochondral ossification (Kronenberg 2003). Chondrogenesis is a 
complex process that leads to establishments of cartilage. During embryogenesis, 
cartilage is the first skeletal tissue to be formed that leads to the formation of all mature 
cartilage and long bones, except flat bones (Quintana, zur Nieden et al. 2009). Flat bone 
is formed through intramembranous ossification, while long bone formation is through 
endochondral ossification. The process of cartilage formation starts when mesenchymal 
stem cells (MSCs) condense to form a dense cell mass. Then MSCs proliferate and 
differentiate into chondroblasts. Some of these cells give rise to mature chondrocytes. If 
mature chondrocytes undergo endochondral ossification, or long bone formation, 
cartilage is vascularized, ECM becomes degraded, hypertrophic chondrocyte become 
apoptotic, and osteoblasts invade the free space within the tissue (Hoffman, Weston et al. 
2003), (Mackie, Ahmed et al. 2008). (Figure 2). As chondrogenesis plays important roles 
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Figure 2 shows the schematic of chondrogenesis and endochondral ossification 
Chondrogenesis can be divided into five main stages, each stage is the occurrence 
of a specific event. (A) Condensation and proliferation of MSCs, (B) 
Differentiation of MSCs into chondroblasts, (C) Chondroblast become 
chondrocytes (D) Mature chondrocytes become hypertrophy, (E) if cartilage 
tissue undergoes endochondral ossification hypertrophic chondrocytes become 
apoptotic,   cartilage   is   vascularized,   and   osteoblasts   invade   the tissue 
(Quintana, zur Nieden et al. 2009) 
 
in the formation of both mature cartilages and bones, any errors occurring during this 
crucial process can affect cartilage formation and long bone formation. 
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Arachidonic acid and leukotriene biosynthesis 
 
Arachidonic acid (AA) is the precursor of prostaglandins and leukotrienes, which 
are lipid signaling molecules. In mammals, Cyclooxygenase 1 and cyclooxygenase 2 
(COX 1 and COX 2) are the key enzymes in prostaglandins biosynthesis, while 5- 
lipoxygenases (5-LO), is a key enzyme in leukotriene biosynthesis. Despite having 
approximately 60% identical primary structures and performing almost the same catalytic 
function (Simmons, Botting et al. 2004), COX 1 is constitutively expressed in most 
tissues, while COX 2 is induced (Tanabe and Tohnai 2002). COX2 metabolizes AA to 
generate cyclo-endoperoxides including prostaglandin H2 (PGH2), which is subsequently 
converted into PGD2, PGE2, PGF2, PGI2, and thromboxane A2 (TXA2). In leukotriene 
biosynthesis, 5-LO converts AA into 5 hydroxy-peroxy-eicosatetraenoic acid (5HPETE), 
which is then converted into intermediate leukotriene A4 (LTA4), then into leukotriene 
B4 (LTB4) by enzyme leukotriene A4 hydrolase (LTA4H), leukotriene C4 (LTC40, 
leukotriene D4 (LTD4), leukotriene E4 (LTE4) by enzyme LTC4 synthase (LTC4S) 
(O'Connor, Manigrasso et al. 2014). (Figure 3). 
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Figure 3: Prostaglandin and Leukotriene biosynthesis (O'Connor, Manigrasso 
et al. 2014) shows schematic of pathway for synthesis and signaling of 
arachidonic acid, docosahexaenoic acid, and eicosapentaenoic acid- 
derived lipid mediators. The diagram summarizes some of the synthetic 
pathways for lipid mediator synthesis. Lipid mediators and synthetic 
intermediates and active products are shown in black text. Enzyme 
activities are shown in red text. Receptors are shown in green text. Known 
effects of receptor activation on intracellular cyclic adenosis 
monophosphate or calcium levels are shown at the bottom. 
. 
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Prostaglandins and leukotrienes biosynthesis have been showed to be important in 
the process of chondrogenesis and endochondral ossification or long bone formation. 
Leukotrienes are very potent inflammatory mediators that can have negative effects on 
long bone healing and cartilage tissue generation. Recent studies have shown that 
decreasing 5-LO activity during long bone fracture can accelerate endochondral 
ossification, decrease healing time, and increase osteogenesis in animal models Other 
studies also proved that leukotriene antagonism, using montelukast sodium which is 
leukotriene type 1 receptor antagonist and zileuton which is a 5-LO enzyme inhibitor, can 
enhance fracture repair on mice modal by increasing chondrocyte proliferation and early 
endochondral bone formation (Wixted, Fanning et al. 2009). Licofelone (ML-3000), a 
dual inhibitor of 5-LO and COX, has been shown to reduce the level of cartilage 
chondrocyte death in vivo in experimental dog osteoarthritis (Boileau, Martel-Pelletier et 
al. 2002). these experimental findings indicate that pharmacological manipulation of the 
arachidonic acid pathway could be a means to accelerate or enhance chondrogenesis. In 
fact, there are a great number of compounds targeting 5-LO or its cofactor, 5- 
Lipoxygenase-Activating factor (FLAP), which have been used to treat chronic 
obstructive pulmonary diseases ((Poff and Balazy 2004), (Carter, Young et al. 1991, 
Evans, Ferguson et al. 2008),(Muller-Peddinghaus, Fruchtmann et al. 1993). In addition, 
compounds targeting leukotriene receptors or prostaglandin receptors have been used to 
treat ophthalmic conditions, asthma, and other medical conditions (Jones, Labelle et al. 
1995), (Alexander, Miller et al. 2002). 
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Relation to public health and purpose of the thesis 
 
As chondrogenesis is the important process in the formation of mature cartilage 
and endochondral ossification (Quintana, zur Nieden et al. 2009), pharmacological 
methods to promote chondrogenesis would be of clinical value for osteoarthritis and long 
bone fractures. Osteoarthritis (OA) is a clinical syndrome that is characterized by 
cartilage degradation that leads to joint failure, in addition to stiffening of joints, and 
functional limitation (Akkiraju and Nohe 2015). With OA, the cartilage within the joint 
pathologically lost hyaline or articular cartilage itself, subchondral sclerosis development, 
osteophyte formation, and meniscus and bone marrow degradation (Joseph, Baum et al. 
2012), ligamentous laxity, and subchondral bone changes (Bennell, Hunter et al. 2012). 
Joints affected by OA are peripheral joints which include large joints such as the knees, 
hips, and small joints such as hand joints. As these joints are important to carry out daily 
activities, the pain from these joints can reduce joint functions and effect on patients’ 
quality of life. Not only does OA impact the individual, OA can also have large impact 
on society, affecting almost 27 million Americans or 12.1% of the adult population. It is 
estimated that the United States spends $185 billion in management of OA annually 
(Neogi 2013). Thus, methods that could regenerate or promote chondrogenesis would be 
of substantial benefit to patients and would reduce the societal burden caused by OA. 
Usually, patients suffering from OA receive both pharmacological ( such as celecoxib, 
rofecoxib, which are nonsteroidal anti-inflammatory drugs or NSAIDS, acetaminophen, 
capsaicin cream) and non-pharmacological treatments (such as exercise, aerobic or 
strengthening or water-based, arthroplasty). Although, these treatment options can relieve 
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symptoms or improve functionality temporarily, pharmacological options are known to 
have adverse side effects such as gastrointestinal (GI) toxicity of NSAIDs and increased 
risk of myocardial associated with rofecoxib (Zhang, Moskowitz et al. 2007). 
In this study, we hypothesize that direct pharmacological inhibition of 5-LO would 
accelerate and enhance chondrogenesis and may contribute to the improved bone healing 
effects observed in the rodent fracture models where 5-LO expression was inhibited 
(Cottrell, Keshav et al. 2013). Our hypothesis was tested with the use of ATDC5 
chondroprogenitor cells treated with a direct 5-LO inhibitor, ABT-761. The ATDC5 cell 
line is derived from the mouse teratocarcinoma cells and has been characterized as a 
chondrogenic cell line which goes through a sequential process analogous to chondrocyte 
differentiation. ATDC5 cell line was chosen over a mice model because these cells are 
easy to handle and their differentiation into chondrocytes is easily detectable and have 
been used to assess for chondrogenesis as previous studies (Choi, Nepal et al. 2011), 
(Altaf, Hering et al. 2006). ABT-761 is a N-hydroxyurea analog which functions as a 
direct 5-LO enzyme inhibitor. ABT-761 exhibits potent and selective inhibition of 
leukotriene formation. As calcium and proteoglycan deposition occur during 
chondrogenesis, quantification of these matrix components is used to assess 
chondrogenesis. 
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Methodology 
 
Cell culture 
 
The ATDC5 cell line was utilized and stored at -80 C when not in use. Cells were 
cultured under 5% CO2 in growth media, which consisted of Dulbecco’s Modified 
Eagle’s Medium (DMEM)/Hams F-12 50/50 (Corning ®, Manassas, Virginia, USA) Mix 
supplemented with 5% fetal bovine serum (FBS), 1% L-Glutamine, 1% 
Penicillin/Streptomycin, 1% Selenium, and 1% Transferrin at 37°C. Cells were checked 
periodically (every 2-3 days) using a Leica DMi1 FOV20 inverted microscope (Leica, 
Chicago, IL, USA) to determine confluence, the possibility of contamination, and cell 
death. When the cells reached 100% of confluence, the experimental treatments were 
conducted as described below. 
 
 
 
ABT-761 treatment 
 
ATDC5 cells were treated with increasing doses of 5-LO inhibitor, ABT-761 
(Abbott, Abbott Park, IL, USA), (1 µM, 10 µM, 100 µM, 1000 µM) in triplicate over 
specific time points (24 and 48 hours, and 1, 2, 3, 4 weeks) and/or with Insulin 
(Invitrogen, Waltham, MS, USA) (INS) at increasing doses (0.1% and 1%). 
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Cellular proliferation 
 
ATDC5 cells were seeded in a 96-well plate at a density of 8000 cells per well 
and allowed to adhere for 24 hours at 37°C in a CO2 incubator. After 24 hours of 
incubation, culture media were replaced with the 12 different treatment groups (media, 
media and 0.1% INS, media and 1% INS, media and 10 µM ABT, media and 10 µM and 
0.1% INS, media and 10 µM ABT and 1% INS, media and 100 µM ABT, media and 
0.1% INS and 100 µM ABT, media and 1% INS and 100 µM ABT, media and 1000 µM 
ABT, media and 0.1% INS and 1000 µM ABT, media and 1% INS and 1000 µM ABT). 
Then the cells were incubated for 24 hours at 37°C in a CO2 incubator. Subsequently, 10 
µL of yellow MTT solution (5 mg/ml in Phosphate-Buffered Saline (PBS), 1X, without 
Calcium and Magnesium, Corning®, Manassas, Virginia, USA) was added to each well 
and the 96-well plate was incubated for 4 hours at 37°C in a CO2 incubator. Then the 
mixture of treatment and MTT solution was aspirated from each well. Next, the formed 
formazan crystals were solubilized by adding 100 µL of Dimethyl Sulfoxide (DMSO), 
(Sigma-Aldrich ®, USA), per well. Each plate was covered with aluminum foil and 
incubated at room temperature for 2 hours while shaking. Finally, the intensity of the 
dissolved intracellular purple formazan crystal was quantified by measuring the 
absorbance at a wavelength of 570 nm using spectrophotometry SpectraMax M5. In order 
to quantify % of cellular proliferation, the absorbance value reading of the blank must be 
subtracted from all samples. Absorbance reading from test samples must then be divided 
by those of the control and multiplied by 100 to give percentage cell viability or 
proliferation. The formula was shown in Figure 4. If the absorbance values are greater 
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Figure 4: formula for determine cellular proliferation 
 
than the control, this indicates increased cell proliferation, but if the absorbance values 
are lower than the control this suggests cell death or inhibition of cellular proliferation. 
 
 
 
 
Immunocytochemistry 
 
ATDC cells were seeded in quadruplet in an 8-chamber polystyrene vessel tissue 
culture treated glass slide (Falcon Corning ®, Big Flats, New York, USA ) at a density of 
80,000 cells/300µL per well and allowed to adhere for 24 hours at 37°C in a CO2 
incubator. After 24 hours of incubation, the culture medium was replaced with 4 different 
treatment groups (media, media and 10 µM ABT, media and 1% INS, media and 1% INS 
and 10 µM ABT). At timepoints of 24 and 48 hours, the immunocytochemistry was 
conducted. First, the media in the chambers was aspirated, then the chamber was washed 
one time with PBS. Next, the cells were fixed in 5 minutes with -20°C methanol. Then, 
the fixative -20°C methanol was aspirated, and the chamber was rinsed 3 times with ice- 
cold PBS. After that, the chambers were incubated with 300 µL blocking reagent, 
SuperBlock™ Blocking Buffer in PBS (Thermo Scientific, Rockford, Illinois, USA ) to 
block unspecific binding for 1 hour at room temperature. Subsequently, the blocking 
reagent was aspirated, and the chambers were incubated with primary antibodies, 5- 
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Lipoxygenase (5-LO) mouse monoclonal antibody, (Santa Cruz Biotechnology, Inc., 
Dallas, Texas, USA) (sc-136195), at 1:25 dilution at 4°C overnight. On the following 
day, the chamber was washed 3 times with PBS), 1X, without Calcium and Magnesium, 
(Corning®, Manassas, Virginia, USA), for 5 minutes and gentle shaking. Then the 
chamber was incubated with secondary antibodies, mouse-IgG kappa BP-HRP which is a 
purified recombinant mouse IgG kappa light chain binding protein conjugated to 
horseradish peroxidase (HRP), (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) 
(sc-516102), at 1:25 dilution for 2 hours. After that, the chambers were washed 3 times 
with PBS for 5 minutes while gently shaking. Next, the chambers were incubated with 
Hydrogen peroxide 30% solution and DAB Substrate System, (VWR Company, Solon, 
Ohio, USA) for 2 to 5 minutes following the manufacturer’s instructions. Then the 
chambers were washed 2 times with diH2O. After that, the safe removal fixture kit was 
used to remove the chamber out of the slide. Finally, the slides were dehydrated through 
alcohol and xylenes as follows: soak in 90% ethanol twice for 3 minutes each, then 100 
% twice for 3 minutes each. Immediately, 1-2 drops of permanent Acrytol Mounting 
Media, (Leica Biosystems, Buffalo Grove, IL, USA) were added on the slides and 
covered with glass coverslips. Each slide was observed by Olympus BX53 Microscope 
at 200X magnification, and Osteomeasure software was used to quantify the DAB 
staining procedure and document the images. 
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Protein Isolation 
 
First, adherent ATDC5 cells treated with six treatment groups (0.1% INS, 1% 
INS, 0.1%INS and 10 µM ABT, 1% INS and 10 µM ABT, 10 µM ABT, and media only) 
were harvested with Mammalian Protein Extraction Buffer (Thermo Fischer Scientific, 
Handouver Park, IL, USA) while on ice. Six different treatment groups were aspirated 
from the plates, rinsed with cold 1x HBSS, then 1X HBSS was aspirated. Mammalian 
Protein Extraction Buffer was added to each well and the plate was placed onto a shaker 
for ten minutes to coat cells evenly while on ice. Next, a cell scraper was used to remove 
adherent cells off the plate, assist in cell lysis, and protein extraction. The protein lysates 
collected from each well were stored in the -20°C freezer until needed for further 
analysis. 
 
 
 
Western Blotting 
 
Triplicate sets of frozen protein samples in Mammalian Protein Extraction Buffer 
were thawed on ice until completely defrosted to prevent protein degradation. In separate 
microtubes, protein sample and 2X SDS with 2-Mercaptoethanol (2-Me) were combined 
in a 1:1 ratio and centrifuged at 4 C. Protein mixture was heated in a dry bath at 70°C for 
10 minutes to denature the protein. A 4-12% NuPAGE Bis-Tri gel (Thermo Fischer 
Scientific, Handover Park, IL, USA) was run using NuPAGE MOPS Running Buffer 
solution (Thermo Fischer Scientific, Handover Park, IL, USA) and run for 50 minutes at 
200V. In preparation for gel transfer, the transfer apparatus and four pieces of filter paper 
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were soaked in a transfer buffer solution with 10-20% methanol; polyvinylidene fluoride 
(PVDF) membrane was also soaked for one minute in methanol only and rinsed in the 
NuPAGE transfer buffer solution. After the running gel was complete, proteins affixed to 
the gel were transferred to the polyvinylidene difluoride (PVDF) membrane following the 
manufacturer’s directions. Following transfer, PVDF membrane was placed in 
SuperBlock solution (ThermoScience, Rockford, IL) and rocked at room temperature for 
1 hour. 
After 1 hour, the PVDF membrane was rinsed 3 times in 1x Transfer Buffer 
Saline with 0.1% TWEEN (TBS-T) for 5 minutes, then placed in primary antibody 
solution, and slowly shaken overnight in 4°C refrigerator. The primary antibody solution 
consisted of 5-Lipoxygenase (5-LO) mouse monoclonal antibody, Santa Cruz 
Biotechnology, Inc., Dallas, Texas, USA (sc-136195, and 0.1% SuperBlock™ Blocking 
Buffer in PBS (Thermo Scientific , Rockford, Illinois, USA ). Internal control for 5-LO 
protein expression is beta-actin gene. After overnight incubation, the PVDF membrane 
was rinsed 3 times in 1X TBS-T for 5 minutes of each rinse, then placed in secondary 
antibody solution, and rocked at room temperature for 1 hour. The second antibody 
solution consisted of anti-mouse IgG-conjugated antibody, TBS-T and 0.1% SuperBlock. 
The membranes were rinsed twice in 1X TBS-T and once in 1X TBS to remove any 
remaining secondary antibodies, then placed in Pierce ® Enhanced Chemiluminescence 
(ECL) Western Blotting substrate (Thermo Fischer, Handover Park, IL, USA) to view 
under UltraViolet light using FluorChem E system (ProteinSimple, San Jose, CA, USA). 
Then the image result was analyzed by using Alpha View software in which the analysis 
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tool and multiplex band analysis tool were used, the 5-LO protein expression 
was normalized using beta-actin gene. 
 
 
 
Alcian Blue Staining 
 
In order to detect proteoglycan deposition, Alcian Blue Assay was used. First, the 
ATDC5 cells were plated in triplicate in 24 well-plate at a density of 50,000 cells/500 µL 
per well. After 2 days of incubation for confluence at 37⁰C in a CO2 incubator, the 
growth media was replaced with 8 different treatment groups  including media, media 
and 1 µM ABT, media and 10 µM ABT, media and 100 µM ABT, media and 1% INS, 
media and 1% INS and 1 µM ABT, media and 1% INS and 10 µM ABT, media and 1% 
INS and 100 µM ABT, and the time points of 1, 2, 3, 4 weeks, the cells were harvested. 
At each time point, on the day 1 of the Assay, the 24-well plates were rinsed twice with 
PBS then fixed with 100% cold methanol for 5 minutes. Next, the plates were stained 
with 0.1% Alcian Blue in 0.1 M HCl overnight at room temperature. The following day, 
the 24-well plates were rinsed 3 times with HBSS. Then, proteoglycan was extracted with 
6 M Guanidine-HCl overnight. Lastly, the proteoglycan concentration was quantified by 
measuring the absorbance at a wavelength of 595 nm using a spectrophotometer. 
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Alizarin Red Staining 
 
In order to detect calcium deposition, Alizarin Red Assay was used. Like Alcian 
Blue Stain protocol, the ATDC5 cells were plated in triplicate in 24 well-plate at a 
density of 50,000 cells/ 500 µL per well. After 2 days of incubation for confluence at 
37°C in a CO2 incubator, the growth media was replaced with 8 different treatment 
groups including media, media and 1 µM ABT, media and 10 µM ABT, media and 100 
µM ABT, media and 1% INS, media and 1% INS and 1 µM ABT, media and 1% INS 
and 10 µM ABT, media and 1% INS and 100 µM ABT. At timepoints of 1, 2, 3, 4 weeks, 
the cells were harvested. The 24-well plates were rinsed 2 times with PBS then fixed with 
10% (v/v) formaldehyde at room temperature for 15 minutes. Next, the plates were rinsed 
2 times with diH2O, and 1 mL of 40 mM Alizarin Red dye solution was pipetted into 
each well. Then, the 24-well plates were incubated for 20 minutes at room temperature. 
After that, the Alizarin Red dye was aspirated, the plates were washed 4 times with 
diH2O while shaking for 5 minutes of each wash. To facilitate the removal of any 
remaining liquid, the plates were left at an angle for 2 minutes and re-aspirated. After 
that, the plates were stored in -20⁰C freezer. On the following day, 800 µL of 10% (v/v) 
of Acetic acid was added to each well, then the plates were incubated at room 
temperature for 30 minutes while shaking. Using a cell scraper, the monolayer was 
scraped from the plate and transferred with 10% (v/v) acetic acid to clean centrifuge 
tubes. The centrifuge tubes were then vortexed briefly for 30 seconds, then warmed for 
10 minutes at 85°C. Afterward, the centrifuge tubes were placed on ice for 5 minutes then 
centrifuged at 13,000 rpm for 15 minutes. Next, 500 µL of supernatant was transferred to 
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new centrifuge tubes. Then, 200 µL of 10% (v/v) ammonium hydroxide was added to the 
supernatant. Finally, 150 µL of supernatant was pipetted in triplicate into a 96-well plate, 
then the calcium deposition was quantified by measuring the absorbance at a wavelength 
of 405 nm using a spectrophotometer. 
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Results 
 
The results of the MTT assay shows that 10µM ABT does not affect cellular 
proliferation compared to the control. However, at higher concentrations, ABT 
significantly inhibits cellular proliferation (Figure 5). 
The MTT assay result shows that 10 µM ABT (Rx3) does not affect cellular 
proliferation (113%, p > 0.05) compared to the controls, including media only (Rx1), 
0.1% INS (Rx2), 1% INS (Rx9). However, at higher concentrations of 1000 µM, 
including Rx3 vs Rx7 (10 µM ABT vs 1000 µM ABT), Rx3 vs Rx8 (10 µM ABT vs 
0.1%INS & 1000 µM), Rx 3 vs Rx12 (10 µM ABT vs 1%INS & 1000 µM), ABT 
significantly inhibits cellular proliferation, which decreases 51.5%, 52,8%, 52% 
respectively, p-value < 0.05. At concentrations of 100 µM, on the other hand, ABT does 
not inhibit cellular proliferation, Rx3 vs Rx5 (10 µM ABT vs 100 µM ABT), p> 0.05. 
Therefore, the concentration of ABT was capped in at 100 µM and one more 
concentration of ABT, which was 1 µM, was added for the following experiments to 
elucidate the effects of ABT on chondrogenesis. It is also noticed that there is no 
difference in the concentration of insulin at 0.1% and 1.0% regarding cellular 
proliferation in the controls group (Rx2 vs Rx9), as well as in the presence of 10 µM 
ABT (Rx4 vs Rx10) (Figure 5), (Table1, 2). 
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Figure 5: Cellular proliferation of ATDC-5 cells post ABT-treatment. ATDC-5 cells 
treated with 10 µM, 100 µM, 1000 µM ABT in combination with 0.1% and 1% insulin 
for 24 hours (Rx3,4,10,5,6,11,7,8,12_treatment groups). 
Control groups included cells treated in media only, and media in combination with 0.1 
% and 1% insulin (Rx1,2,9). 
(A) The absorbance value of ATDC5 cell in each treatment group at 24 hours-post 
treatment. 
(B) Cellular proliferation values calculated for ATDC5 cells in each treatment group at 
24 hours-post treatment. 
(C) Image of wells for each ATDC5 cell treatment group after completion of MTT assay. 
Error bars represented Mean +/- SD. Photographed by the author, Tien My Tran, at 
Seton Hall University, South Orange, New Jersey, USA, in May 2019. 
(*) denoted statistically significant differences between treatment groups where 
appropriate; corresponding p-value were noted. 
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One Way Analysis of Variance 
 
Group Name 
SEM 
Mean Std Dev 
RX 2 (0.1%INS) 
6.240 
116.983 10.808 
RX 9 (1.0%INS) 
17.643 
82.516 30.559 
RX 3 (10 uM ABT) 
19.453 
113.068 33.693 
RX 4 (0.1%INS &10 uM ABT) 
8.408 
103.685 14.563 
RX 10 (1.0%INS & 10 uM ABT ) 
4.753 
75.554 8.232 
RX 5 (100 uM ABT) 
4.711 
65.866 8.160 
RX 6 (0.1%INS & 100 uM ABT) 
7.267 
64.916 12.587 
RX 11 (1%INS & 100 uM ABT) 
8.604 
50.257 14.903 
RX 7 (1000 uM ABT) 
2.691 
61.615 4.660 
RX 8 (0.1%INS & 1000 uM ABT) 
2.985 
60.303 5.171 
RX 12 (1%INS & 1000 uM ABT) 
6.840 
61.475 11.846 
Table 1: cellular proliferation percentage in each treatment group compare to control 
(Rx1) which is 100% 
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Comparison 
P P<0.050 
Diff of Means (%) t 
RX 2 vs. RX 11 (0.1%INS vs 1%INS & 100 uM ABT) 
0.002 Yes 
66.725 5.083 
RX 3 vs. RX 11 (10 uM ABT vs 1%INS & 100 uM ABT) 
0.005 Yes 
62.811 4.785 
RX 2 vs. RX 8 (0.1%INS vs 0.1%INS & 1000 uM ABT) 
0.015 Yes 
56.680 4.318 
RX 2 vs. RX 12 (0.1%INS vs 1%INS & 1000 uM ABT) 
0.018 Yes 
55.507 4.229 
RX 2 vs. RX 7 (0.1%INS vs 1000 uM ABT) 
0.019 Yes 
55.368 4.218 
RX 4 vs. RX 11 (10 uM ABT & 0.1%INS vs 1%INS & 100 uM ABT) 
0.027 Yes 
53.427 4.070 
RX 3 vs. RX 8 (10 uM ABT vs 0.1%INS & 1000 uM ABT ) 
0.030 Yes 
52.766 4.020 
RX 2 vs. RX 6 (0.1%INS vs 0.1%INS & 100 uM ABT) 
0.033 Yes 
52.067 3.966 
RX 3 vs. RX 12 (10 uM ABT vs 1%INS & 1000 uM ABT ) 
0.036 Yes 
51.593 3.930 
RX 3 vs. RX 7 (10 uM ABT vs 1000 uM ABT ) 
0.036 Yes 
51.454 3.920 
RX 2 vs. RX 5 (0.1%INS vs 100 uM ABT ) 
0.038 Yes 
51.117 3.894 
RX 1 vs. RX 11 (media only vs 1%INS & 100 uM ABT) 
0.048 Yes 
49.743 3.789 
RX 3 vs. RX 1 (10 uM ABT vs media only ) 
1.000 No 
13.068 0.996 
RX 2 vs. RX 3 (0.1%INS vs 10 uM ABT) 
1.000 No 
3.914 0.298 
RX 3 vs. RX 9 (10 uM ABT vs 1.0% INS) 
0.669 No 
30.552 2.327 
RX 3 vs. RX 5 (10 uM ABT vs 100 uM ABT) 
0.074 No 
47.203 3.596 
RX 2 vs. RX 9 (0.1%INS vs 1.0% INS) 
0.458 No 
34.466 2.626 
RX 4 vs. RX 10 (10 uM ABT & 0.1%INS vs 10 uM ABT & 1%INS) 
0.799 No 
28.131 2.143 
Table 2: statistical analysis for the cellular proliferation in each treatment group of the 
MTT assay in Figure 1. 
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The Immunocytochemistry shows ATDC5 cells do express 5-Lipoxygenase (5- 
LO) protein in growth and differentiation phase, and the 5-LO protein can be inhibited in 
the presence of the inhibitor, ABT-761 (Figure 6,7). The results of 
Immunocytochemistry show that at both 24 and 48-hour post-treatment, there is an 
increase in 5-LO protein expression in both only media group (Rx1) and 1%INS group 
(Rx9). However, the 5-LO protein expression decreases in the presence of 10 µM ABT 
(Rx3_only 10 µM ABT, and Rx 10_1%INS+10 µM ABT). 
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Figure 6: Immunocytochemistry of ABT-treated ATDC5 cells. ATDC5 cells were plated 
at 50% and allowed to reach confluency, then the media was replaced with 4 treatment 
groups: Rx1 (just Media), Rx3 (10µM ABT), Rx9 (1%INS), Rx10 (10µM ABT + 1% 
INS). Subsequently, the Immunocytochemistry was conducted at two time points: 24 
hours-post treatments (A, B, C, D), and 48 hours-post treatments (E, F, G, H). ATDC5 
cells stained for 5-LO protein using the primary antibody, 5-Lipoxygenase (5-LO) mouse 
monoclonal antibody, (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) (sc-136195) 
and then DAB substrate. Finally, 5-LO protein expression can be visualized as brown 
spots, which are denoted by orange arrows. Photographed by the author, Tien My Tran, 
at Rutgers University, Newark, New Jersey, USA, in May 2019. 
 
 
 
 Rx1 _ Media Rx3_1uM ABT Rx9_1% INS Rx10_1uM ABT + 1%INS 
24 hours post Rx 74 45 96 41 
 85 37 93 37 
 89 52 104 44 
48 hours post Rx 93 48 107 67 
 96 37 100 63 
 99 48 97 67 
Table 3: Brown spot counting data using an Olympus BX53 Microscope at 200X 
magnification, and Osteomeasure software 
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Figure 7: Number of 5-LO protein expression differences among 4 treatment groups: 
Rx1_only Media, Rx3_1 µM of ABT, Rx9_1% INS, Rx10_1µM ABT + 1%INS. At both 
time points at 24 and 48 hours post-treatment, 5-LO protein expression decreases in both 
treatment groups Rx3 (10 µM ABT) and Rx10 (1% INS+10 µM ABT) compared to the 
Rx1 (media only) and Rx9 (1.0% INS) (p<0.05), which are denoted by pink and blue 
starts. At timepoint of 24 hours post-treatment, 5-LO protein expression increases in Rx9 
(1.0% INS) versus Rx1 (only Media), which is denoted by light blue stars. At time point 
of 48 hours, 5-LO protein expression increases in Rx10 (1% INS+10 µM ABT) versus 
Rx3 (10 µM ABT), which is denoted by red star. When compared to 48 hours post- 
treatment, 5-LO protein expression in Rx 1 (only media) and Rx 10 (1% INS+10 µM 
ABT) increase in 24 hours post treatment. In contrast, there are no differences in 5-LO 
protein expression in Rx3 (10 µM ABT) and Rx9 (1.0% INS) in both time points. 
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Comparison  
P<0.050 
Diff of Means t P 
24 hours post treatment 
(Rx9 vs Rx10) 1.0% INS vs 1 µM ABT + 1.0% INS 
Yes 
57.000 10.992 <0.001 
(Rx9 vs Rx3) 1.0% INS vs 1 µM ABT 
Yes 
53.000 10.221 <0.001 
(Rx1 vs Rx10) Media only vs 1 µM ABT + 1.0% INS 
Yes 
42.000 8.100 <0.001 
(Rx1 vs Rx3) Media only vs 1 µM ABT 
Yes 
38.000 7.328 <0.001 
(Rx9 vs Rx1) 1.0% INS vs Media only 
Yes 
15.000 2.893 0.040 
(Rx3 vs Rx10) 1 µM ABT vs 1 µM ABT + 1.0% INS 
No 
4.000 0.771 0.463 
48 hours post treatment 
(Rx9 vs Rx3) 1.0% INS vs 1 µM ABT 
Yes 
57.000 15.513 <0.001 
(Rx1 vs Rx3) Media only vs 1 µM ABT 
Yes 
51.667 14.062 <0.001 
(Rx9 vs Rx10) 1.0% INS vs 1 µM ABT + 1.0% INS 
Yes 
35.667 9.707 <0.001 
(Rx1 vs Rx10) Media only vs 1 µM ABT + 1.0% INS 
Yes 
30.333 8.256 <0.001 
(Rx10 vs Rx 3) 1 µM ABT + 1.0% INS vs 1 µM ABT 
Yes 
21.333 5.806 <0.001 
(Rx9 vs Rx1) 1.0% INS vs Media only 
No 
5.333 1.452 0.185 
24 hours vs 48 hours post treatment 
Rx1 Media only  
Yes 
13.333 3.502 0.008 
Rx 10 1 µM ABT + 1.0% INS 
Yes 
25.000 6.565 <0.001 
Rx3 1 µM ABT  
No 
0.333 0.0655 0.949 
Rx9 1.0% INS  
No 
3.667 0.721 0.742 
Table 4: statistical analysis for 5-LO protein expression in 4 treatment groups in Figure 8 
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The Alcian Blue stain showed that treatment with ABT-761 has negative effect on 
matrix proteoglycan deposition (Figure 8) At week 1, the proteoglycan deposition of at 
treatment groups (Rx3’_1µM ABT, Rx3_10µM ABT, Rx5_100µM ABT, 
Rx10_1%INS+10µM ABT, Rx11_1%INS+100µM ABT) is lower compared to the 
positive control (Rx9_1%INS) (p<0.05), except treatment group Rx10’_1%INS+1µM 
ABT. Once again, at week 2, the proteoglycan production at all treatment groups 
including Rx10’ is lower than positive control Rx9 (p<0.05)(Figure 9). However, Rx3 
(10µM ABT) and Rx11 (1%INS+100µM ABT) is lower than negative control Rx1 (only 
Media) (p<0.05)(Figure 9, E, F, C, D). Especially, Rx 3’(only 1µM ABT) and 
Rx10’(1%INS+1µM ABT) are higher than Rx3, Rx5, Rx11 at which there are a higher 
concentration of ABT (p<0.05). Thus, from week 2, there is a possibility of higher 
concentrations of ABT which might decrease proteoglycan production has emerged. At 
week 3, as there is no statistically significant difference between proteoglycan production 
in all treatment groups compared to positive control Rx9 (1%INS) (p>0.05), in other 
words, proteoglycan production in all treatment groups starts increasing compared to 
decreasing in week 1, and week 2. Also, Rx3’ (1µM ABT) shows higher proteoglycan 
deposition versus Rx3 (10µM ABT), Rx5 (100µM ABT), Rx10 (1%INS+10µM ABT), 
Rx11 (1%INS+100µM ABT). This further strengthens the possibility that higher 
concentrations of ABT can inhibit proteoglycan production. Finally, at week 4, once 
again, Rx3’(1µM ABT) and Rx10’(1%INS+1µM ABT) strongly show higher 
proteoglycan deposition versus Rx3 (10µM ABT), Rx5 (100µM ABT), Rx10 
(1%INS+10µM ABT), Rx11 (1%INS+100µM ABT) (p<0.01). Thus, the Alcian blue 
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staining assay result showed that at a concentration of 1µM, ABT-761 has no effect on 
proteoglycan deposition of ATDC5 chondrogenic cell line, however, at higher 
concentrations, including 10µM and 100µM, ABT-761 has negative effects on 
proteoglycan deposition. Alizarin Red Stain also shows that treatment with ABT-761 
also has negative effects on calcium deposition of ATDC5 chondrogenic cell line. 
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Figure 8: Matrix proteoglycan production in ABT-treated ATDC5 cells overtime. (A) 
Quantification of 1uM ABT Treatment groups (B) Images of 1uM ABT Treatment 
Groups (C) Quantification of 10uM ABT Treatment groups (D) Images of 10uM ABT 
Treatment Groups (E) Quantification of 100uM ABT Treatment groups (F) Images of 
10uM ABT Treatment Group. Photographed by the author, Tien My Tran, at Seton Hall 
University, South Orange, New Jersey, USA, in May 2019. 
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Figure 9: Matrix Calcium Deposition in ABT-treated ATDC5 cells overtime. (A) 
Quantification of 1uM ABT Treatment groups (B) Images of 1uM ABT Treatment 
Groups (C) Quantification of 10uM ABT Treatment groups (D) Images of 10uM ABT 
Treatment Groups (E) Quantification of 100uM ABT Treatment groups (F) Images of 
10uM ABT Treatment Groups. Photographed by the author, Tien My Tran, at Seton 
Hall University, South Orange, New Jersey, USA, in May 2019 .
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Discussion 
 
ABT-761, a new potent 5-Lipoxygenase inhibitor which effectively inhibits 
leukotriene formation has been evaluated both in vitro and in vivo for the treatment of 
leukotriene-dependent human diseases. In animal studies, the compound has shown it 
potentials in different disease models, including potently attenuates bronchoconstriction 
and pulmonary inflammation in rodent (Bell, Harris et al. 1997), or inhibit eosinophil 
influx into lungs of Brown Norway rats (Namovic, Walsh et al. 1996), or attenuates 
cerebral vasospasm in rabbit model of subarachnoid hemorrhage (Barbosa, Arthur et al. 
2001). In fact, ABT-761 is under development for the treatment of asthma in both adults 
and children (Reid 2001),(Wong, Kearns et al. 1998). Although, there are studies 
demonstrated that pharmacological inhibition of 5-Lipoxygenase can accelerate and 
enhances fracture healing or bone formation (Cottrell and O'Connor 2009), (Cottrell, 
Keshav et al. 2013), (Saul, Weber et al. 2019). there are no direct studies focusing on the 
effects of ABT-761 on chondrogenesis. In this study, through the MTT assay, we found 
that ABT-761 at a concentration of 10 µM has no effect on cellular proliferation 
compared to the controls (p>0.05) (Figure 5). However, at higher concentrations, 
including 100 µM and 1000µM, ABT-761 significantly inhibits cellular proliferation, 
which decreases to 63% and 52% respectively, (p<0.05) (Figure 5, Table 2). In addition, 
we found that insulin concentration does not make any difference in cellular proliferation 
in the presence of ABT (p>0.05), (Figure 5, Table 2). Our data is similar to Steinhibler et 
al, who demonstrated that many 5-LO inhibitors have anti-proliferative effects. 
Therefore, moving forward from the MTT assay, we omitted the concentration of 1000 
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µM, and only used the two concentration of ABT-761 at 10 µM,100 µM, and added one 
new concentration of 1 µM to elucidate the effects of ABT-761. 
In this study, using immunocytochemistry and immunoblotting, we showed that 
ATDC5 cells, which derived from mouse teratocarcinoma chondrogenic cell-like, do 
express 5 Lipoxygenase protein, in both proliferation and differentiation phases. 5- 
Lipoxygenase is a key enzyme in the metabolism of arachidonic acid to leukotriene. 5- 
lipoxygenase expression has been shown in various tissue, such as human brain with 
traumatic injury and astrocytoma, which is a form of brain tumor, has increased 
expression of 5-LO that was demonstrated by immunohistochemistry (Zhang, Zhang et 
al. 2006). In addition, using immunofluorescence and immunohistochemistry, 5- 
Lipoxygenase (5-LO) and 15-Lipoxygenase-1 (15-LO-1) have been demonstrated to be 
present in rheumatoid arthritis and osteoarthritis synovium, with 5-LO being mostly 
expressed in-lining and sub-lining macrophages, neutrophils and mast cells, and 15-LO-1 
mainly in lining macrophages, fibroblasts, and sub-lining endothelial cells (Gheorghe, 
Korotkova et al. 2009). Leukotriene B4 (LTB4) is a potent chemoattractant associated 
with the development of osteoarthritis (OA), its receptors BLT1 and BLT2 have found in 
human synovium, subchondral bone as well as in cartilage cells or chondrocytes (Hansen, 
Indrevik et al. 2015). In this study, using immunocytochemistry and immunoblotting, we 
show that ATDC5 cells, which derived from mouse teratocarcinoma chondrogenic cell- 
like, do express 5 Lipoxygenase protein, in both proliferation and differentiation phases, 
in treatments with media only (Rx1) and 1%INS (Rx9) (p<0.01). Nevertheless, the 5-LO 
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protein expression is decreased in the presence of the inhibitor, ABT-761 (Rx3_10 µM 
ABT and Rx10_ 1%INS+10 µM ABT)(p<0.001) (Figures 6,7,8). 
In vertebrates, longitudinal bone growth occurs by a process called endochondral 
ossification, which takes place in the growth plates of long bones. Chondrocytes secrete 
cartilage matrix, proliferate and differentiate into hypertrophic cells during this process, 
resulting in progressive widening of the growth plate ((De Luca, Uyeda et al. 2000). There 
are many factors that can influence the longitudinal growth of bone. Nutrition, hormonal, 
and mechanical factors can all have effects on cell proliferation, hypertrophy, death and 
bone formation. In this study, we demonstrated that at a concentration of 1 µM ABT-761 
(Rx3’), there is no increase nor decrease on proteoglycan deposition as well as calcium 
deposition compared to controls (Rx1_Media only and Rx9_1%INS) (p<0.05). Moreover, 
we strongly found that at higher concentrations of 10 µM (Rx3) and 100 µM of ABT-761 
(Rx5), ABT-761 adversely inhibits proteoglycan production or calcium deposition 
(p<0.001) (Figures 9.10). In other words, these high concentrations of ABT-761 have 
negative effects on chondrogenesis as chondrogenesis is characterized by calcium 
deposition and proteoglycan matrix synthesis. Furthermore, as shown in 
immunocytochemistry assay (Figures 6,7) and immunoblotting assay (Figure 8), in the 
presence INS with ABT-761, 5-LO protein decreases as in the presence of inhibitor ABT- 
761 only (Figure 9,10). The markedly negative effects on chondrogenesis of ABT-761 can 
contribute to the bone formation by accelerating apoptosis of cartilage, which is 
explained by the fact that during chondrogenesis, to promote endochondral ossification, 
the mature chondrocytes or cartilage cells must undergo hypertrophy, then apoptosis to 
allow cartilage 
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become vascularized and osteoblasts invade the cartilage tissue (Quintana, zur Nieden et 
al. 2009). From other research that shows that 5-LO causes acceleration in the process of 
endochondral ossification and results in the earlier detection of late chondrocyte genes 
(Cottrell and O'Connor 2009). 
Overall, our experiment results show that treatment with 1µM ABT-761 has no 
effect on chondrogenesis, neither increase nor decrease, in ATDC5 cells, a mouse 
chondrogenic cell line. In contrast, concentrations of 10 µM and 100µM ABT-761 has 
negative effects on chondrogenesis through which ABT-761 promotes chondrocyte 
apoptosis that may potentially lead to accelerating endochondral ossification or long bone 
formation in patients with a long bone fracture. However, ABT-761 may not be a clinical 
value to regenerate or promote chondrogenesis in patients suffering from osteoarthritis. 
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